Association between statin use and the risk, prognosis of gynecologic cancer: A meta-analysis

Chen, Yali; Han, Ling; Zheng, Ai

doi:10.1016/j.ejogrb.2021.11.013

Cited by 11 publications

(4 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, the proportion of malignant tumor patients in the statins group was lower than in the non-statins group with a significant difference. Many studies have confirmed that statins can reduce the incidence rate of endometrial cancer, ovarian cancer, esophageal cancer, gastric cancer and colorectal cancer [ 16 , 17 ]. In addition, statins can also reduce the mortality of patients with esophageal cancer, gastric cancer, colorectal cancer, prostate cancer and breast cancer [ 17 , 18 ].…”

Section: Discussionmentioning

confidence: 99%

A retrospective study on the effect of statins on mortality and antimicrobial resistance among patients with <i>Staphylococcus aureus</i> bloodstream infection

Su,

Wang,

Zhong

et al. 2024

Arch Med Sci

View full text Add to dashboard Cite

IntroductionThere is insufficient evidence in statin on the treatment of Staphylococcus aureus (SA) infection, we observe and analyze the clinical outcomes and antibiotic resistance of SA bloodstream infections in patients who received statins.Material and methodsA retrospective study was carried out in SA bloodstream infection of hospitalized patients from January 2018 to August 2023. The 30-day attributable mortality, 30-day all-cause mortality and clinical data of patients who received statins and non-statins were compared.ResultsA total of 74 patients with SA bloodstream infection were included, 32 (43.2%) patients received treatment with statins and 42 (56.8%) with non-statins. The incidence of methicillin-resistant SA (MRSA) was significantly lower in the statins group (15.6% vs. 38.1%, p = 0.034), however, no significant differences were observed in the mortality rate (p = 0.410).ConclusionsThis study revealed the superiority of statins in reducing incidence of MRSA among SA bloodstream infection patients, but statins do not improve the 30-day mortality rate.

show abstract

Section: Discussionmentioning

confidence: 99%

A retrospective study on the effect of statins on mortality and antimicrobial resistance among patients with <i>Staphylococcus aureus</i> bloodstream infection

Su,

Wang,

Zhong

et al. 2024

Arch Med Sci

View full text Add to dashboard Cite

show abstract

“…The association between statin use and prognosis has been revealed in several types of cancers by meta-analysis. Chen et al [ 11 ] demonstrated that statin use was associated with lower mortality rates in endometrial cancer (HR = 0.71, 95% CI: 0.64–0.80) and ovarian cancer (HR = 0.78, 95% CI: 0.73–0.83). Xu et al [ 28 ] included 7 studies involving 24,441 cases and showed that post-diagnostic statin use was related to better RFS (HR = 0.74, 95% CI: 0.57–0.98), OS (HR = 0.53, 95% CI: 0.31–0.91), and CSS (HR = 0.61, 95% CI: 0.41–0.91) in breast cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…[10] A number of studies have shown that statin use is related to a decreased risk for several types of cancer, including prostate cancer, gastric cancer, gynecologic cancer, colorectal cancer and esophageal cancer. [11][12][13][14][15] Statin users show a significantly lower risk of esophageal cancer than nonstatin users. [16] Furthermore, statin use is associated with improved long-term survival and the risk of mortality in some types of cancer.…”

Section: Introductionmentioning

confidence: 99%

The association between statin use and prognosis in esophageal cancer patients: A meta-analysis

Lv¹,

Chen²,

Wu³

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: The impact of statin use on the survival of esophageal cancer patients remains unclear now. The aim of this study was to identify the relationship between statin use and the long-term survival of esophageal cancer patients. Methods: The PubMed, EMBASE, and Web of Science databases were searched up to August 20, 2022, for relevant studies. The endpoints included overall survival (OS), cancer-specific survival (CSS), recurrence-free survival, and hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were pooled to assess the association between statin use and the prognosis of esophageal cancer patients. Subgroup analysis based on the pathological type (adenocarcinoma vs squamous cell carcinoma), dose of statin use and tumor stage (tumor-node-metastasis I–III vs IV) was further performed. All statistical analyses were conducted using STATA 12.0 software. Results: A total of 7 retrospective studies involving 25,711 participants were included in this meta-analysis. The pooled results indicated that statin use was significantly associated with improved OS (HR = 0.80, 95% CI: 0.74–0.87, P < .001), CSS (HR = 0.77, 95% CI: 0.74–0.89, P < .001), and recurrence-free survival (HR = 0.38, 95% CI: 0.16–0.87, P = .022). Furthermore, subgroup analysis stratified by the pathological type, dose of statin use and tumor stage for OS and CSS showed similar results and indicated the protective role of statin use in the prognosis of esophageal cancer patients. Conclusion: Statin use is significantly associated with improved long-term survival of esophageal cancer patients and might serve as a promising prognostic indicator in esophageal cancer. However, more prospective high-quality studies are still needed to verify our findings.

show abstract

“…Numerous publications have evaluated the relationship between statins and various types of cancer [ 26 , 27 ]. Though robust evidence for a positive relationship between statin use and reduced cancer risk has not been conclusively shown for all cancer types, several large, diverse, population-based epidemiologic studies note a lower cancer incidence and/or mortality in populations treated with statins, including for cancers such as colorectal [ 28 – 30 ], prostate [ 31 – 33 ], gastric [ 34 ], pancreatic [ 35 , 36 ], liver [ 37 – 40 ], breast and cervical [ 41 , 42 ], endometrial and ovarian [ 43 , 44 ], and lymphoma [ 45 , 46 ].…”

Section: Main Textmentioning

confidence: 99%

Can statins lessen the burden of virus mediated cancers?

Clark

Ahmed

Chang

et al. 2022

Infect Agents Cancer

View full text Add to dashboard Cite

Background Oncogenic viruses, including hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), Epstein Barr virus (EBV), and Kaposi Sarcoma Herpes virus (KSHV) contribute to a significant proportion of the world’s cancers. Given the sizeable burden of virus mediated cancers, development of strategies to prevent and/or treat these cancers is critical. While large population studies suggest that treatment with hydroxymethylglutaryl-CoA reductase inhibitors, commonly known as statins, may reduce the risk of many cancer types including HBV/HCV related hepatocellular carcinoma, few studies have specifically evaluated the impact of statin use in populations at risk for other types of virus mediated cancers. Main body Studies of populations with HBV and HCV suggest a protective, dose-dependent effect of statins on hepatocellular carcinoma risk and support the theory that statins may offer clinical benefit if used as chemoprophylactic agents to reduce liver cancer incidence. However, no population level data exists describing the impact of statins on populations with other oncogenic viral infections, such as HPV, EBV, and KSHV. Conclusion Further study of statin use in diverse, global populations with or at high risk for oncogenic viral infections is essential to determine the impact of statin therapy on virus mediated cancer risk.

show abstract

Association between statin use and the risk, prognosis of gynecologic cancer: A meta-analysis

Cited by 11 publications

References 63 publications

A retrospective study on the effect of statins on mortality and antimicrobial resistance among patients with <i>Staphylococcus aureus</i> bloodstream infection

A retrospective study on the effect of statins on mortality and antimicrobial resistance among patients with <i>Staphylococcus aureus</i> bloodstream infection

The association between statin use and prognosis in esophageal cancer patients: A meta-analysis

Can statins lessen the burden of virus mediated cancers?

Contact Info

Product

Resources

About